A Phase 3 interventional study of Optivate® (Human Coagulation Factor VIII) in Haemophilia A, sponsored by Bio Products Laboratory. Completed at 8 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-02-15.
Sponsored by Bio Products Laboratory · Phase 3, Interventional, and Treatment
The main objective of the study is to investigate the safety and efficacy of Optivate®, administered in appropriate dosage to present bleeding and achieve haemostasis in patients with Haemophilia A undergoing surgery.
866 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
Browse Hemophilia A studies →Bio Products Laboratory is the lead sponsor of 27 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-
Optivate® (Human Coagulation Factor VIII)
Biological: Optivate® (Human Coagulation Factor VIII)
Incremental Recovery for plasma Factor VIII
Incremental recovery is defined as peak rise in plasma Factor VIII levels divided by Factor VIII dose in IU/KG
Time frame: 90 minutes after pre-operative bolus dose
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bio Products Laboratory